Diabetes Type 2

From 2001 to 2017, the estimated prevalence of youth-onset T1D and T2D increased approximately 45% and 95%, respectively, according to a new study.

Finerenone, in patients with mild-to-moderate renal disease and T2D, reduced CV event risk by 13% and risk for a composite renal event by 23%, study authors reported at ESC 2021.

The ESC Congress 2021, Aug 27-30, 2021, is here. For primary care, we highlight the "Hot Lines" clinical trial presentations where new data from novel trials will premier.